Literature DB >> 31782719

Isolated testicular vasculitis due to immune checkpoint inhibitor.

Rebecca Weiner1, Britt Hanson2, Jamaal Rehman3, Bob Sun4.   

Abstract

Immune checkpoint inhibitors are increasingly being used to treat various malignancies; consequently, more rheumatological side effects, ranging from arthritis to vasculitis, are being reported. Here we present, for the first time, a case of vasculitis involving the testicle in the setting of an immune checkpoint inhibitor. As reported in previous cases, recurrence of a malignancy, as opposed to vasculitis, was initially suspected, thus creating a diagnostic dilemma. These rheumatological side effects have garnered attention as they potentially provide a window into in the pathogenesis of rheumatological diseases.

Entities:  

Year:  2019        PMID: 31782719      PMCID: PMC7001997          DOI: 10.5152/eurjrheum.2019.19061

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  11 in total

1.  Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.

Authors:  David R Minor; Stephen R Bunker; Judith Doyle
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 2.  Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.

Authors:  Maria E Suarez-Almazor; Sang T Kim; Noha Abdel-Wahab; Adi Diab
Journal:  Arthritis Rheumatol       Date:  2017-03-03       Impact factor: 10.995

Review 3.  Immune checkpoint dysfunction in large and medium vessel vasculitis.

Authors:  Ryu Watanabe; Hui Zhang; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

4.  Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

Authors:  Barbara L Goldstein; Lydia Gedmintas; Derrick J Todd
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

Review 5.  The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.

Authors:  Cornelia M Weyand; Gerald J Berry; Jörg J Goronzy
Journal:  J Leukoc Biol       Date:  2017-12-29       Impact factor: 4.962

6.  Vasculitis associated with immune checkpoint inhibitors-a systematic review.

Authors:  Anisha Daxini; Keri Cronin; Antoine G Sreih
Journal:  Clin Rheumatol       Date:  2018-06-19       Impact factor: 2.980

Review 7.  Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Clifton O Bingham; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

8.  Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Augusto Vaglio; Yaping Joyce Liao; Kenneth J Warrington; Jörg J Goronzy; Cornelia M Weyand
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

9.  Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.

Authors:  Joshua S Manusow; Leila Khoja; Nataly Pesin; Anthony M Joshua; Efrem D Mandelcorn
Journal:  J Immunother Cancer       Date:  2014-12-16       Impact factor: 13.751

10.  Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Authors:  Alfred Zippelius; Frank Stenner-Liewen; Heinz Läubli; Jürgen Hench; Michal Stanczak; Ingmar Heijnen; Alexandros Papachristofilou; Stephan Frank
Journal:  J Immunother Cancer       Date:  2017-06-20       Impact factor: 13.751

View more
  1 in total

Review 1.  Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Konstantinos Melissaropoulos; Kalliopi Klavdianou; Alexandra Filippopoulou; Fotini Kalofonou; Haralabos Kalofonos; Dimitrios Daoussis
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.